First Quadrant L Pca Lowers stake in Amgen (AMGN)

Amgen (AMGN) : First Quadrant L Pca reduced its stake in Amgen by 0.11% during the most recent quarter end. The investment management company now holds a total of 347,398 shares of Amgen which is valued at $56,712,724 after selling 391 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Amgen makes up approximately 1.21% of First Quadrant L Pca’s portfolio.

Other Hedge Funds, Including , Catawba Capital Management Va boosted its stake in AMGN in the latest quarter, The investment management firm added 775 additional shares and now holds a total of 4,035 shares of Amgen which is valued at $658,714. Amgen makes up approx 0.16% of Catawba Capital Management Va’s portfolio.Carroll Financial Associates boosted its stake in AMGN in the latest quarter, The investment management firm added 840 additional shares and now holds a total of 5,373 shares of Amgen which is valued at $877,142. Amgen makes up approx 0.14% of Carroll Financial Associates’s portfolio.Factory Mutual Insurance Co reduced its stake in AMGN by selling 14,000 shares or 7.84% in the most recent quarter. The Hedge Fund company now holds 164,600 shares of AMGN which is valued at $26,421,592. Amgen makes up approx 0.34% of Factory Mutual Insurance Co’s portfolio.Campbell Newman Asset Management Inc reduced its stake in AMGN by selling 756 shares or 0.98% in the most recent quarter. The Hedge Fund company now holds 76,392 shares of AMGN which is valued at $12,262,444. Amgen makes up approx 2.18% of Campbell Newman Asset Management Inc’s portfolio.Indiana Trust Investment Management Co boosted its stake in AMGN in the latest quarter, The investment management firm added 75 additional shares and now holds a total of 2,234 shares of Amgen which is valued at $344,639. Amgen makes up approx 0.18% of Indiana Trust Investment Management Co’s portfolio.

Amgen opened for trading at $162.45 and hit $163.65 on the upside on Wednesday, eventually ending the session at $163.25, with a gain of 0.47% or 0.76 points. The heightened volatility saw the trading volume jump to 21,61,425 shares. Company has a market cap of $122,636 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.